References
- Baek, S. J., Wilson, L. C. and Eling, T. E. 2002. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23, 425-434. https://doi.org/10.1093/carcin/23.3.425
- Bavaresco, L. 2003. Role of viticultural factors on stilbene concentrations of grapes and wine. Drugs Exp Clin Res 29, 181-187.
- Brigstock, D. R. 2003. The CCN family: a new stimulus package. J Endocrinol 178, 169-175. https://doi.org/10.1677/joe.0.1780169
- Chien, W., Kumagai, T., Miller, C. W., Desmond, J. C., Frank, J. M., Said, J. W. and Koeffler, H. P. 2004. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 279, 53087-53096. https://doi.org/10.1074/jbc.M410254200
- Chung, E. Y., Kim, B. H., Hong, J. T., Lee, C. K., Ahn, B., Nam, S. Y., Han, S. B. and Kim, Y. 2011. Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem 22, 902-909. https://doi.org/10.1016/j.jnutbio.2010.07.012
- Chuang, J. Y., Yu, N. Y., Chiang, I. P., Lai, C. H., Lin, C. D. and Tang, C. H. 2012. Cyr61 increases matrix metalloproteinase- 3 expression and cell motility in human oral squamous cell carcinoma cells. J Cell Biochem 113, 1977-1986. https://doi.org/10.1002/jcb.24066
- Delmas, D., Lançon, A., Colin, D., Jannin, B. and Latruffe, N. 2006. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 7, 423-442. https://doi.org/10.2174/138945006776359331
- Dhar, A. and Ray, A. 2010. The CCN family proteins in carcinogenesis. Exp Oncol 32, 2-9.
- Kim, J. S., Jang, M. J., Kim, H. Y., Kim, S. Y. and Sohn, H. Y. 2007. Analysis of differentially expressed genes by resveratrol using membrane microarray. J Life Sci 17, 1115-1120. https://doi.org/10.5352/JLS.2007.17.8.1115
- Kim, Y. A., Lee, W. H., Choi, T. H., Rhee, S. H., Park, K. Y. and Choi, Y. H. 2003. Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int J Oncol 23, 1143-1149.
- O'Kelly, J., Chung, A., Lemp, N., Chumakova, K., Yin, D., Wang, H. J., Said, J., Gui, D., Miller, C. W., Karlan, B. Y. and Koeffler, H. P. 2008. Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol 33, 59-67.
- Park, M. H., Kwak, E. H., Sohn, H. Y., Eling, T. E. and Kim, J. S. 2011. Global gene expression changes by several phytochemicals in human colorectal cancer cell. J Life Sci 21, 1219-1225. https://doi.org/10.5352/JLS.2011.21.9.1219
- Perbal, B. 2004. CCN proteins: multifunctional signalling regulators. Lancet 363, 62-64. https://doi.org/10.1016/S0140-6736(03)15172-0
- Rayalam, S., Yang, J. Y., Ambati, S., Della-Fera, M. A. and Baile, C. A. 2008. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res 22, 1367-1371. https://doi.org/10.1002/ptr.2503
- Rizvi, S. I. and Pandey, K. B. 2010. Activation of the erythrocyte plasma membrane redox system by resveratrol: a possible mechanism for antioxidant properties. Pharmacol Rep 62, 726-732. https://doi.org/10.1124/pr.110.002733
- Tong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W. and Koeffler, H. P. 2004. Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta- catenin-c-myc-p53 pathway. Oncogene 23, 4847-4855. https://doi.org/10.1038/sj.onc.1207628
- Udenigwe, C. C., Ramprasath, V. R., Aluko, R. E. and Jones, P. J. 2008. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 66, 445-454. https://doi.org/10.1111/j.1753-4887.2008.00076.x
- Vogelstein, B., Lane, D. and Levine, A. J. 2000. Surfing the p53 network. Nature 408, 307-310. https://doi.org/10.1038/35042675
- Whitlock, N. C., Bahn, J. H., Lee, S. H., Eling, T. E. and Baek, S. J. 2011. Resveratrol-induced apoptosis is mediated by early growth response-1, Krüppel-like factor 4, and activating transcription factor 3. Cancer Prev Res (Phila) 4, 116-127. https://doi.org/10.1158/1940-6207.CAPR-10-0218